+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma



Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma



Pediatric Pulmonology 7(2): 89-93



In this placebo-controlled, double-blind, single-dose study the new beta-2-agonist formoterol (one puff, 12 micrograms) was intraindividually compared with salbutamol (one puff, 100 micrograms) for onset, magnitude, and duration of bronchodilating efficacy in 15 young asthmatics aged 5 to 14 years with mild to severe asthma. All but one had regular antiasthmatic medication before beginning the study, but none was oral steroid dependent. Both medications produced rapid bronchodilatation within 10 minutes, reflected by a decrease in specific airway resistance (sRaw) with maximum effects at 10 minutes (salbutamol, 51%) and 30 minutes (formoterol, 60%). Significant bronchodilation was present at 10 minutes to 2 hours after inhalation of salbutamol and at 30 minutes to 8 hours after formoterol. Mean percent improvement over baseline was higher for formoterol at all measured times from 30 minutes to 12 hours, when 55% mean decrease in sRaw was still present. The effect of salbutamol was a less than 10% mean decrease in sRaw after 6 hours. The differences in sRaw decrease between the two medications were statistically significant at 4 to 10 hours after inhalation. Neither medication administered as an aerosol caused cardiac side effects. Both had a rapid onset of action and a comparable maximal effect. However, at the doses studied, formoterol produced a larger decrease in sRaw from baseline for longer periods after inhalation than did salbutamol.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040166251

Download citation: RISBibTeXText

PMID: 2797925

DOI: 10.1002/ppul.1950070207


Related references

Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily. Ugeskrift for Laeger 154(47): 3325-3328, 1992

Comparison of formoterol a new long acting beta agonist with salbutamol and placebo in children with asthma. Journal of Allergy & Clinical Immunology 83(1): 185, 1989

Comparative Study of Carbuterol and Salbutamol from Metered Aerosols in Bronchial Asthma. Respiration 35(4): 220-223, 1978

Comparative study of carbuterol and salbutamol from metered aerosols in bronchial asthma. Respiration; International Review of Thoracic Diseases 35(4): 220-223, 1978

Comparison of the bronchodilating efficacy of two salbutamol aerosols. Current Therapeutic Research 42(2): 346-350, 1987

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 45(4): 259-261, 1990

Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. Journal of Allergy and Clinical Immunology 84(6 Pt 1): 891-895, 1989

Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. European Journal of Medical Research 1(10): 465-470, 1996

Salbutamol by metered dose inhaler plus holding chamber is more effective than salbutamol by jet nebulizer for the treatment of acute childhood asthma. European Respiratory Journal 8(SUPPL 19): 13S, 1995

Single dose comparison of salbutamol and a fenoterol/ipratropium combination from metered aerosols in patients with asthma. New Zealand Medical Journal 99(803): 420-421, 1986

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease: A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy (Copenhagen) 50(8): 657-663, 1995

Comparison of the bronchodilating efficacies of a novel salbutamol metered dose powder inhaler and a pressurised metered dose aerosol with a spacer. Arzneimittel-Forschung 48(9): 919-923, 1998

Early bronchodilating effect of a new oral beta-2-receptor agonist (broxaterol) in bronchial asthma. Respiration; International Review of Thoracic Diseases 53(4): 220-224, 1988

Early Bronchodilating Effect of a New Oral Beta-2-Receptor Agonist (Broxaterol) in Bronchial Asthma. Respiration 53(4): 220-224, 1988

A comparison of salbutamol and terbutaline aerosols in bronchial asthma. Practitioner 211(266): 801-804, 1973